Benzene is a well-known leukemogen associated with acute myeloid leukaemia (AML) particularly at high exposure ([@bib15]; [@bib9]; [@bib11]). This paper presents detailed results for AML and chronic lymphoid leukaemia (CLL) from a pooled study of three updated case--control studies, nested within three cohort studies of male petroleum workers in Canada ([@bib18]), the United Kingdom ([@bib16]) and Australia ([@bib7]).

Materials and Methods
=====================

The methodology has been described in detail elsewhere ([@bib19]). In brief, new cases of lymphohaematopoietic (LH) cancers occurring through 2006 were identified using national mortality and cancer incidence registries and, additionally, for the Australian study, by self-report (*n*=3) if confirmed by medical documentation. A random selection (with replacement) of four age-matched control subjects (five for the Australian study) per case were selected that were alive and LH cancer-free at the time of their respective case diagnosis. The Canadian and UK controls were also oil-company matched.

Available diagnostic information was used by two haematopathologists to classify, using a predetermined and agreed set of criteria, the first occurrence of a relevant diagnosis according to both the International Classification of Diseases (ICD) and World Health Organization (WHO) ([@bib12]) schemes; because the results were similar, we report on the more recent WHO scheme. The hematopathologists scored the diagnosis certainty (high, medium or low) using diagnostic term specificity, source documentation quality and agreement between source records (high: complete specification by appropriate diagnostic terms and cytogenetic information; medium: same but no cytogenetic information; and low: disagreement between source records or ambiguity).

Work histories were constructed from company records for the UK and Canadian studies and by interview (with validation by company records where possible) in the Australian study ([@bib1], [@bib14], [@bib6]). Country- and era-specific measured exposure data for specific jobs and tasks were used to derive shift-averaged quantitative estimates of benzene exposure concentration (parts per million (p.p.m.)) (base-estimates (BE)). These were applied to each work-history line and adjusted for differences in workplace, materials, tasks and/or environment to give a workplace exposure (WE) (p.p.m.). A job exposure certainty score (high=3, medium=2, or low=1) was allocated based on (a) job duties, (b) facility characteristics/technology, (c) products handled, (d) job-specific BE robustness (high: all four criteria met; medium: one of b-d lacking but job duties reasonably certain; low: \>b-d lacking or job duties unknown). An overall career exposure certainty score was calculated by weighting job-specific WEs by the number of years spent at each level of certainty. Six exposure metrics were derived: cumulative exposure (p.p.m.-years); duration of employment (years); average exposure intensity (p.p.m.); maximum exposure intensity (p.p.m.); peak exposure (at least 1 year in job with \>3 p.p.m. exposure for 15--60 min at least weekly) (Yes/No); dermal exposure (the highest job-specific relative probability of skin contact for at least a year) (none, low, medium, high).

Smoking data were collected where available from workplace records and through interview for the Australian study.

Statistical analyses included conditional logistic regression to assess the relationship between LH cancers relative to benzene exposure and with penalised smoothing splines (P-splines) to examine potential dose--response relationships. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated relative to a background benzene concentration for benzene exposure metric tertiles, with cut-points based on exposure distributions among controls. Subgroup analyses were conducted specific to study, facility type and job. SAS version 9.2 was used for analyses ([@bib17]).

Ethical approval for the combined study and recruitment of new subjects was obtained from the relevant ethics committees.

Results
=======

There were 60 cases of AML (241 controls) and 80 cases of CLL (345 controls). Mean average intensity of benzene exposure for AML cases and controls was 0.18 p.p.m. and 0.2 p.p.m., respectively, and for CLL cases and controls was 0.19 p.p.m. and 0.21 p.p.m., respectively.

Acute myeloid leukaemia
-----------------------

Odds ratios for AML rise as cumulative exposure, duration of exposure, peak exposure and dermal exposure increase but no clear pattern emerges for average or maximum intensity of exposure ([Table 1](#tbl1){ref-type="table"}). Sensitivity analyses by disease certainty and exposure certainty did not strengthen these results nor did restricting the exposure window to 2--20 years before case diagnosis ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Penalised spline curves ([Figure 1](#fig1){ref-type="fig"}) do not show a compelling dose--response relationship with continuous benzene exposure metrics, although cumulative exposure for AML hints at a possible relationship (AML p~spline~=0.14). The OR for AML associated with peak exposure is raised ([Table 1](#tbl1){ref-type="table"}), and ORs generally increase with increasing probability of dermal exposure; these patterns strengthened for Terminal Workers who are usually the highest exposed workers, for example, for peak exposure OR=1.62, (95% CI: 0.83, 3.16).

For those participants where smoking data were available, 16 out of 22 cases and 67 out of 95 controls smoked (OR: 1.5, 95% CI: 0.44, 5.14).

The magnitude of the ORs differed by study, with a tendency for reduced ORs for the Canadian study and increased non-significant ORs for the UK and Australian studies for all exposure metrics.

The risk of AML for ever being a tanker driver (mostly based at terminals) for at least 1 year was statistically significantly raised (OR: 2.02, 95% CI: 1.08, 3.78) (30 cases, 82 controls) as was the risk for tanker drivers who had ever worked at a terminal (OR: 2.41, 95% CI: 1.21, 4.80) (21 cases, 85 controls).

Chronic lymphoid leukaemia
--------------------------

In contrast to the results for AML, there was no increase or decrease in risk with any of the exposure metrics for CLL either as continuous variables ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) or in categorical analyses ([Table 1](#tbl1){ref-type="table"}). Categorical analyses gave raised ORs with the highest OR for duration in tertile 2 (OR: 2.14, 95% CI: 1.08, 4.23), although showing a downward trend. The spline analyses also suggested an association with duration of employment. Similar results were found for medium or high diagnosis certainty score with a strengthening of the relationship for duration (Tertile 2 OR: 2.36, 95% CI: 1.16, 4.81). Analysis of those with a medium or high job confidence score showed increased ORs in all categories of the three exposure metrics with significant excesses for tertile 3 ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

There was no relationship with continuous metrics for the Canadian and UK studies but increases in the Australian study for cumulative exposure (OR: 1.06, 95% CI: 1.00, 1.12), maximum benzene exposure intensity (OR: 1.45, 95% CI: 0.79, 2.69) and average benzene exposure intensity (OR: 2.27, 95% CI: 0.64, 8.02). Similar patterns were found in categorical analyses ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). However, the reference categories for the Australian study contain small numbers of cases, and there is a tendency for ORs to decrease in the last tertiles. Combining the first 2 categories of each of the metrics in [Supplementary Table S3](#sup1){ref-type="supplementary-material"} for the Australian study greatly reduced the OR: for cumulative exposure\>2.93 p.p.m.-years (OR: 1.75, 95% CI: 0.71, 4.36) and reduced the ORs in all categories in the other metrics while showing the same patterns. Those who had ever worked in a refinery in the Australian study showed similar patterns of results compared with those who had never worked in a refinery ([Table 2](#tbl2){ref-type="table"}), although generally ORs were much higher in those who had ever worked in a refinery.

Discussion
==========

Overall, this study did not show a strong or consistent relationship between benzene exposure and AML or CLL. The study has high quality, precise benzene exposure estimates for individual participants, tailored to their job title, site and era and high quality diagnoses. Key components of the study analysis were replicated and confirmed by a second independent analyst. Potential limitations include small numbers in some subgroup analyses, no information on potential confounders, such as alcohol use, radiation exposure and genetic susceptibility, and a paucity of smoking data. Consistently elevated risks of about 1.5 for AML and smoking suggest smoking is not a potent confounder ([@bib20]).

The lack of a strong relationship between AML and benzene exposure differed from the original studies, which had some patterns of increased risk, particularly in the Australian study ([@bib7]).

A strong relationship of AML with high exposures to benzene has been shown ([@bib5]). We found lower ORs for AML than for MDS, where a strong dose--response relationship with benzene was found ([@bib19]). This may reflect the fact that our exposures were generally low; they are similar to typical current European and North American exposures of ⩽1 p.p.m. ([@bib21]; [@bib4]). Our tertiles of cumulative exposure, defined as ⩽0.348, 0.348--2.93, \>2.93 p.p.m.-years, are much lower than the low cumulative exposure category of \<40 p.p.m.-years in [@bib13] (meta-OR: 1.94, 95% CI: 0.95, 3.95) and those found in studies such as the Pliofilm ([@bib5]) and Chinese occupational studies ([@bib8]; [@bib22]).

Some AMLs from our earlier studies were reclassified to MDS or myeloproliferative disease (MPD) after examination of pathology information; MDS and MPD can progress to AML ([@bib2]). Before ICD-10, MDS and MPD were not available diagnostic categories and many of our cases occurred before this, particularly in the older UK study; the more recent Australian cases were more likely to have been correctly identified.

In contrast to the patterns for MDS ([@bib19]) the AML results were not consistent across the three studies, although risks for tanker drivers and in particular at terminals were similarly raised in the two diseases.

The patterns for CLL tended to be different between the three studies with the Australian study showing increased risk in several analyses and particularly for refinery work (similar to the earlier Australian nested case-control ([@bib7])). Elevated CLL mortality has previously been identified in refinery populations ([@bib10].

CLL is considered a subtype of non-Hodgkin lymphoma (NHL), as both are lymphoid cell malignancies ([@bib12]). A review of 68 industrial studies reported several elevated findings for lymphoid cancers (CLL, NHL, multiple myeloma) for rubber workers and cohorts exposed to multiple chemicals ([@bib3]). Possibly a more complex environment such as a refinery compared with terminals might tend to show an increased risk for lymphoid tumours such as CLL.

Conclusion
==========

While some patterns among terminal workers, who tend to have a relatively high benzene exposure, suggest a relationship between AML and benzene, the overall evidence does not persuasively demonstrate a risk between benzene and AML. However, exposures in this study may have been too low to observe this. There was a general lack of association between benzene and CLL; the tendency for higher risks to occur in refinery workers may point to a role of more diverse exposures.
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Click here for additional data file.

###### 

Click here for additional data file.

![**Penalised splines for benzene exposure metrics for AML and sensitivity analyses on disease and exposure history certainty.** Log odds ratio of risk of LH cancer subtype as a smooth function of the binary logarithm of cumulative (p.p.m.-years +0.001), average (p.p.m.), and maximum exposure (p.p.m.). In panel **D**, log odds ratios are plotted against duration on an additive scale. More certain cases refer to those with medium or high case certainty, and subjects with more certain exposure history refer to those with medium or high job history confidence scores. (**A**) AML: Cumulative benzene exposure (p.p.m.-years). (**B**) AML: average intensity of benzene exposure (p.p.m.). (**C**) AML: maximum intensity of benzene exposure (p.p.m.). (**D**) AML: duration of employment (years).](bjc2013780f1){#fig1}

###### Odds ratios and 95% confidence intervals for acute myeloid leukaemias and chronic lymphoid leukaemias for benzene exposure metrics

                                                                         **Acute myeloid leukaemia**   **Chronic lymphoid leukaemia**               
  --------------------------------------------------------------------- ----------------------------- -------------------------------- ------------ -------------------
  **Cumulative benzene exposure beyond zero (p.p.m.-years)**                                                                                        
  ⩽0.348                                                                          20**/**89                          1                    24/117             1
  \>0.348--2.93                                                                   19**/**83                  1.04 (0.50, 2.19)            32/110     1.49 (0.81, 2.76)
  \>2.93                                                                          21**/**69                  1.39 (0.68, 2.85)            24/118     1.05 (0.56, 1.98)
  **Maximum benzene exposure intensity (p.p.m.) beyond 0.016 p.p.m.**                                                                               
  ⩽0.016                                                                          17**/**87                          1                    30/106             1
  \>0.016--0.118                                                                  13**/**47                  1.49 (0.65, 3.37)          14**/**86    0.55 (0.26, 1.18)
  \>0.118--0.413                                                                  14**/**55                  1.35 (0.59, 3.07)          21**/**78    0.97 (0.50, 1.87)
  \>0.413                                                                         16**/**52                  1.65 (0.75, 3.63)          15**/**75    0.72 (0.36, 1.45)
  **Average benzene exposure intensity (p.p.m.) beyond 0.016 p.p.m.**                                                                               
  ⩽0.016                                                                          16**/**90                          1                    31/114             1
  \>0.016--0.081                                                                  15**/**46                   1.97 (0.87, 4.5)          15**/**76    0.74 (0.36, 1.5)
  \>0.081--0.259                                                                  13**/**55                   1.41 (0.61, 3.3)          19**/**86    0.83 (0.42, 1.62)
  \>0.259                                                                         16**/**50                  1.90 (0.86, 4.18)          15**/**69    0.83 (0.41, 1.67)
  **Duration of employment beyond zero (years)**                                                                                                    
  \>0--15.6                                                                      27**/**115                          1                  18**/**105           1
  \>15.6--28                                                                      16**/**77                  0.96 (0.46, 2.01)            36/115     2.14 (1.08, 4.24)
  \>28                                                                            17**/**49                  1.70 (0.75, 3.87)            26/125     1.22 (0.57, 2.60)
  **Peak exposure (ever \>3 p.p.m. for 1+years)**                                                                                                   
  None                                                                             25/124                            1                    50/187             1
  Yes                                                                              35/117                    1.50 (0.82, 2.75)            30/138     0.69 (0.41, 1.14)
  **Dermal exposure**                                                                                                                               
  None                                                                              22/87                            1                    29/113             1
  Low                                                                               0/16                            ---                    8/24      1.41 (0.56, 3.53)
  Medium                                                                            11/39                    1.10 (0.46, 2.61)            16/74      0.82 (0.41, 1.66)
  High                                                                              27/99                    1.15 (0.60, 2.22)            27/134     0.76 (0.42, 1.39)

Abbreviations: CI=confidence interval; p.p.m.=parts per million.

###### Odds ratios and 95% confidence intervals for chronic lymphoid leukaemias and specific benzene exposure metrics for the Australian study ever employed at a refinery and ever not employed at a refinery

                                                                         **Ever employed at refinery**  **Not ever employed at a refinery**          
  --------------------------------------------------------------------- ------------------------------- ------------------------------------- ------ --------------------
  **Cumulative benzene exposure beyond zero (p.p.m.-years)**                                                                                         
  ⩽0.348--2.93                                                                       3/15               1                                      7/20  1
  \>2.93                                                                             9/11               3.75 (0.76, 18.55)                     4/13  0.71 (0.16, 3.27)
  **Maximum benzene exposure intensity (p.p.m.) beyond 0.016 p.p.m.**                                                                                
  ⩽0.016--0.118                                                                    2**/**13             1                                      4/17  1
  \>0.118--0.413                                                                    7**/**8             5.65 (0.87, 36.83)                     3/8   1.74 (0.27, 11.19)
  \>0.413                                                                           3**/**5             2.33 (0.34, 15.91)                     4/8   1.83 (0.32, 10.53)
  **Average benzene exposure intensity (p.p.m.) beyond 0.016 p.p.m.**                                                                                
  ⩽0.016--0.081                                                                    2**/**10             1                                      5/17  1
  \>0.081--0.259                                                                   7**/**11             2.98 (0.53, 16.71)                     2/10  0.66 (0.10, 4.61)
  \>0.259                                                                           3**/**5             2.07 (0.27, 15.87)                     4/6   1.67 (0.32, 8.70)
  **Duration of employment beyond zero (years)**                                                                                                     
  ⩽15.6--28                                                                        6**/**13             1                                      9/28  1
  \>28                                                                             6**/**13             1.14 (0.10, 12.66)                     2/5   0.63 (0.05, 7.49)

Abbreviations: CI=confidence interval; p.p.m.=parts per million.
